NEW YORK, January 9, 2020 – Eight leading care delivery systems from across the country have been designated as founding charter members of NASHNET and Centers of Excellence (COEs).
Tag: non-alcoholic fatty liver disease
PM360 Announces NASHNET, pioneered by The Kinetix Group, as a Finalist for Its 2019 Trailblazer Award
NEW YORK, August 27, 2019 – NASHNET has been selected as a finalist in the 11th annual PM360 Trailblazer Awards within the Product/Service Launch category. NASHNET is a unique, care delivery model for the treatment of non-alcoholic fatty liver disease (NAFLD) that was founded and launched in 2018 by The Kinetix Group (TKG). TKG has been chosen alongside reputable marketing firms and industry powerhouses for this award.
The Kinetix Group Partners with Rimidi to Launch a Clinical Care Partnership for the Management of Nonalcoholic Steatohepatitis (NASH)
NEW YORK, August 30, 2018 – The Kinetix Group in partnership with Rimidi, an Atlanta-based health care technology firm, announced a partnership focused on improving Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) care delivery leveraging NASHNET, a global centers of excellence network.
The Nonalcoholic Steatohepatitis (NASH) Network in Collaboration with Echosens Launches a Real World Evidence Model
NEW YORK, August 23, 2018 – The global NASH market is projected to reach $21.5 billion by 2025, with NASH being the leading cause of liver transplantation in the US in the coming years. 1 The NASH Network (NASHNET), in collaboration with The Kinetix Group, has launched a Real World Evidence study to optimize care delivery for patients with Non-Alcoholic Steatohepatitis (NASH). This initiative is in partnership with Echosens, the innovators and marketers of the FibroScan® family of products.